Multiomics study of nonalcoholic fatty liver disease

[1]  Bjarni V. Halldórsson,et al.  Large-scale integration of the plasma proteome with genetics and disease , 2021, Nature Genetics.

[2]  G. Abecasis,et al.  Genome‐wide association analysis of serum alanine and aspartate aminotransferase, and the modifying effects of BMI in 388k European individuals , 2021, Genetic epidemiology.

[3]  M. Cule,et al.  Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning , 2021, eLife.

[4]  S. Cockell,et al.  Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis , 2021, Hepatology.

[5]  Yan V. Sun,et al.  Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes , 2021, Nature Communications.

[6]  M. Moriguchi,et al.  The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease , 2021, Genes.

[7]  Nicholette D. Palmer,et al.  Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology , 2021, Nature Communications.

[8]  A. Sanyal,et al.  SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH , 2021, Hepatology communications.

[9]  Anushya Muruganujan,et al.  PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API , 2020, Nucleic Acids Res..

[10]  Astrid Gall,et al.  Ensembl 2021 , 2020, Nucleic Acids Res..

[11]  F. Pattou,et al.  Exome-wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease. , 2020, Gastroenterology.

[12]  Mary E. Haas,et al.  Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. , 2020, Gastroenterology.

[13]  H. Stefánsson,et al.  Data Resource Profile: The Copenhagen Hospital Biobank (CHB). , 2020, International journal of epidemiology.

[14]  R. Vasan,et al.  Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels—Brief Report , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Mingfeng Xia,et al.  Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver , 2020, Journal of lipid research.

[16]  A. Kulkarni,et al.  Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities , 2020, Frontiers in Medicine.

[17]  Jibiao Wu,et al.  An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease , 2020, BioMed research international.

[18]  Alejandro F Frangi,et al.  The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions , 2020, Nature Communications.

[19]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[20]  J. Pihlajamäki,et al.  LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover , 2020, Gut.

[21]  Tom M Palmer,et al.  Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis , 2020, PLoS medicine.

[22]  Spiros C. Denaxas,et al.  Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure , 2020, Nature Communications.

[23]  K. Huse,et al.  Loss of hepatic Mboat7 leads to liver fibrosis , 2020, Gut.

[24]  Matthew R. Robinson,et al.  Accurate, scalable and integrative haplotype estimation , 2019, Nature Communications.

[25]  H. Ullum,et al.  DBDS Genomic Cohort, a prospective and comprehensive resource for integrative and temporal analysis of genetic, environmental and lifestyle factors affecting health of blood donors , 2019, BMJ Open.

[26]  P. Tsao,et al.  Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations , 2019, Nature Communications.

[27]  Mary E. Haas,et al.  A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease , 2019, bioRxiv.

[28]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  Soumik Basu Ray.  PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease , 2019, Adipocyte.

[30]  Jimmy D Bell,et al.  Measurement of liver iron by magnetic resonance imaging in the UK Biobank population , 2018, PloS one.

[31]  Xu Wang,et al.  Association of sex hormone-binding globulin with nonalcoholic fatty liver disease in Chinese adults , 2018, Nutrition & Metabolism.

[32]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[33]  A. Kasprzak,et al.  Insulin-Like Growth Factor (IGF) System in Liver Diseases , 2018, International journal of molecular sciences.

[34]  Samuel E. Jones,et al.  Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry , 2018, bioRxiv.

[35]  Alexander E. Lopez,et al.  A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease , 2018, The New England journal of medicine.

[36]  E. Chartampilas.  Imaging of nonalcoholic fatty liver disease and its clinical utility , 2018, Hormones.

[37]  N. Risch,et al.  A large electronic health record-based genome-wide study of serum lipids , 2018, Nature Genetics.

[38]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[39]  Pim van der Harst,et al.  Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease , 2017, Circulation research.

[40]  David A. Knowles,et al.  Annotation-free quantification of RNA splicing using LeafCutter , 2017, Nature Genetics.

[41]  P. Visscher,et al.  Multi-trait analysis of genome-wide association summary statistics using MTAG , 2017, Nature Genetics.

[42]  Nicola J. Rinaldi,et al.  Genetic effects on gene expression across human tissues , 2017, Nature.

[43]  Kari Stefansson,et al.  Graphtyper enables population-scale genotyping using pangenome graphs , 2017, Nature Genetics.

[44]  Hannes P. Eggertsson,et al.  Whole genome characterization of sequence diversity of 15,220 Icelanders , 2017, Scientific Data.

[45]  C. Anania,et al.  The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease , 2017, Children.

[46]  E. Disse,et al.  EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? , 2017, Diabetologia.

[47]  Stefan Neubauer,et al.  Characterisation of liver fat in the UK Biobank cohort , 2017, PloS one.

[48]  F. Lammert,et al.  PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[49]  H. Pan,et al.  Activation of farnesoid X receptor promotes triglycerides lowering by suppressing phospholipase A2 G12B expression , 2016, Molecular and Cellular Endocrinology.

[50]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[51]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[52]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[53]  Anders Albrechtsen,et al.  Weighting sequence variants based on their annotation increases power of whole-genome association studies , 2016, Nature Genetics.

[54]  C. Sirlin,et al.  Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE , 2016, Alimentary pharmacology & therapeutics.

[55]  G. Davey Smith,et al.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression , 2015, International journal of epidemiology.

[56]  Bjarni V. Halldórsson,et al.  Large-scale whole-genome sequencing of the Icelandic population , 2015, Nature Genetics.

[57]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[58]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[59]  Chang Liu,et al.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. , 2015, World journal of gastroenterology.

[60]  V. Wong,et al.  PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease , 2015, Journal of gastroenterology and hepatology.

[61]  M. Daly,et al.  LD Score regression distinguishes confounding from polygenicity in genome-wide association studies , 2014, Nature Genetics.

[62]  A. Hamsten,et al.  TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content , 2014, Proceedings of the National Academy of Sciences.

[63]  Qian-qian Zhang,et al.  Insulin‐like growth factor binding protein‐related protein 1 contributes to hepatic fibrogenesis , 2014, Journal of digestive diseases.

[64]  J. Marrero,et al.  The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis , 2014, The American Journal of Gastroenterology.

[65]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[66]  A. Butterworth,et al.  Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data , 2013, Genetic epidemiology.

[67]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[68]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[69]  Tatiana Foroud,et al.  ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry , 2011, Molecular Psychiatry.

[70]  P. Fisher,et al.  Insulin-like Growth Factor–Binding Protein-7 Functions as a Potential Tumor Suppressor in Hepatocellular Carcinoma , 2011, Clinical Cancer Research.

[71]  N. Lundbom,et al.  Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. , 2011, The American journal of clinical nutrition.

[72]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[73]  Chi-wai Wong,et al.  Hepatocyte nuclear factor‐4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A2 GXIIB , 2011, Hepatology.

[74]  Witold R. Rudnicki,et al.  Feature Selection with the Boruta Package , 2010 .

[75]  G. Marchesini,et al.  Insulin resistance in nonalcoholic fatty liver disease. , 2010, Current pharmaceutical design.

[76]  R. Zechner,et al.  Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. , 2009, American journal of physiology. Endocrinology and metabolism.

[77]  Nicola L. Beer,et al.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver , 2009, Human molecular genetics.

[78]  M. Kearney,et al.  IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis , 2009, Trends in Endocrinology & Metabolism.

[79]  N. Schork,et al.  Heritability of nonalcoholic fatty liver disease. , 2009, Gastroenterology.

[80]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[81]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[82]  Jingfei Ma.  Dixon techniques for water and fat imaging , 2008, Journal of magnetic resonance imaging : JMRI.

[83]  Pall I. Olason,et al.  Detection of sharing by descent, long-range phasing and haplotype imputation , 2008, Nature Genetics.

[84]  S. Reeder,et al.  Multiecho reconstruction for simultaneous water‐fat decomposition and T2* estimation , 2007, Journal of magnetic resonance imaging : JMRI.

[85]  F. Bittner,et al.  Identification of the Missing Component in the Mitochondrial Benzamidoxime Prodrug-converting System as a Novel Molybdenum Enzyme* , 2006, Journal of Biological Chemistry.

[86]  G. Gold,et al.  Iterative decomposition of water and fat with echo asymmetry and least‐squares estimation (IDEAL): Application with fast spin‐echo imaging , 2005, Magnetic resonance in medicine.

[87]  L. E. Hammond,et al.  Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. , 2005, Cell metabolism.

[88]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[89]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[90]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[91]  R. Coleman,et al.  Enzymes of triacylglycerol synthesis and their regulation. , 2004, Progress in lipid research.

[92]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[93]  Richard A. Johnson,et al.  A new family of power transformations to improve normality or symmetry , 2000 .

[94]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[95]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[96]  H. Sul,et al.  Expression and identification of p90 as the murine mitochondrial glycerol-3-phosphate acyltransferase. , 1993, Biochemistry.

[97]  G. Braemer.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[98]  W. Sly,et al.  Cloning, sequencing, and expression of cDNA for human beta-glucuronidase. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[99]  G. Kostner,et al.  The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. , 1979, FEBS letters.

[100]  A. Yoshida,et al.  Molecular abnormality of human alpha1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[101]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[102]  J. E. Ghory.  CHILDREN'S MEDICAL CENTER. , 1964, Cincinnati journal of medicine.